A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment

BACKGROUND AND OBJECTIVES: Lorlatinib is approved (100 mg once daily [QD]) for the treatment of patients with anaplastic lymphoma kinase- (ALK) positive metastatic non-small cell lung cancer. This study evaluated the impact of varying degrees of renal impairment on the safety and pharmacokinetics of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Swan, Gong, Jason, Canas, George C., Winkle, Peter, Pelletier, Kathleen, LaBadie, Robert R., Ginman, Katherine, Pithavala, Yazdi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917008/
https://www.ncbi.nlm.nih.gov/pubmed/35018553
http://dx.doi.org/10.1007/s13318-021-00747-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917008/
https://www.ncbi.nlm.nih.gov/pubmed/35018553
http://dx.doi.org/10.1007/s13318-021-00747-4

Ejemplares similares